Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 52-Week High at $52.25

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) reached a new 52-week high during trading on Wednesday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.95 and a current ratio of 1.36. The stock has a market cap of $10.78 billion, a P/E ratio of 18.86 and a beta of 0.33. The firm’s 50 day moving average is $51.66 and its 200 day moving average is $51.51.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.85 EPS for the quarter. The firm had revenue of $659.94 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 18.18% and a return on equity of 30.58%. Analysts anticipate that Recordati Industria Chimica e Farmaceutica S.p.A. will post 2.81 EPS for the current year.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.